| Original language | English (US) |
|---|---|
| Article number | 140 |
| Journal | Blood cancer journal |
| Volume | 11 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2021 |
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood cancer journal, Vol. 11, No. 8, 140, 08.2021.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
AU - Wang, Yucai
AU - Achenbach, Sara J.
AU - Rabe, Kari G.
AU - Shanafelt, Tait D.
AU - Call, Timothy G.
AU - Ding, Wei
AU - Kenderian, Saad S.
AU - Muchtar, Eli
AU - Leis, Jose F.
AU - Koehler, Amber B.
AU - Schwager, Susan M.
AU - Cerhan, James R.
AU - Slager, Susan L.
AU - Kay, Neil E.
AU - Parikh, Sameer A.
N1 - Funding Information: The conduct of this research was supported in part by the Henry J. Predolin Foundation. Funding Information: YW: Research funding (to the institution) from Incyte, InnoCare, Norvatis, and Genentech. Participation in advisory board meetings of Eli Lilly and TG Therapeutics (not personally compensated). WD: Research funding from Merck and DTRM. Advisory board: Merck and Octapharma (no personal compensation). SSK: SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis), Humani-gen (through Mayo Clinic), Morphosys (through Mayo Clinic), Tolero (through Mayo Clinic), and Mettaforge (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, Leahlabs and Lentigen. SSK has participated in consultancy with Torque, Leahlabs, and Kiniksa. SSK has participated in scientific advisory board meetings of Juno, Kite, and Humanigen, and data safety monitoring board meetings of Humanigen. NEK: Research funding from Acerta Pharm, Pharmacyclics, MEI Pharma, and Tolero. Data safety monitoring committee for Agios Pharm, Celgene, Sunesis, Cytomx Therapeutics, Morpho-Sys, Rigel Pharm and Juno Therapeutics. Advisory Board for Astra Zeneca, Cytomx Therapeutics, Pharmacyclics Dava Oncology, Acerta Pharma BV, and Juno Therapeutics. TDS: Research support to institution from Pharmacyclics, Genentech, AbbVie. SAP: Research funding (to the institution) from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP is a principal investigator. Participation in advisory board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Innate Pharma, and AbbVie (not personally compensated). The other authors declare no competing interests.
PY - 2021/8
Y1 - 2021/8
UR - http://www.scopus.com/inward/record.url?scp=85111957927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111957927&partnerID=8YFLogxK
U2 - 10.1038/s41408-021-00532-1
DO - 10.1038/s41408-021-00532-1
M3 - Letter
C2 - 34354039
AN - SCOPUS:85111957927
SN - 2044-5385
VL - 11
JO - Blood cancer journal
JF - Blood cancer journal
IS - 8
M1 - 140
ER -